GLP-1 Receptor Agonist and GIP/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction Authors: Joshua Reitz, Daniel B Rosoff, Pal Pacher, Falk W Lohoff Published: 2026 ABSTRACT AbstractThe co-occurrence of metabolic dysfunction and heavy alcohol consumption contributes substantially to global morbidity, particularly through its impact on liver disease progression. Glucagon-like peptide-1 receptor (GLP1R) agonists and glucose-dependent insulinotropic polypeptide receptor (GIPR)/GLP1R dual agonists, currently approved for the treatment of diabetes and obesity and under investigation for metabolic dysfunction–associated steatohepatitis, are considered for repurposing to reduce alcohol consumption and stabilize metabolic health in heavy-drinking populations. This review summarizes existing evidence, highlights ongoing research, and outlines key unanswered questions regarding this therapeutic potential and the paradigm shift toward metabolic circuit–based interventions in addiction treatment. The dual-target GIPR/GLP1R approach could fill a critical gap for individuals struggling with both heavy alcohol consumption and metabolic dysfunction.Keywords: Alcohol-associated liver disease, Alcohol use disorder, Glucagon-like peptide-1 receptor agonists, Glucose-dependent insulinotropic polypeptide receptor agonists, Metabolic dysfunction, Psychiatry Alcohol misuse, obesity, and metabolic dysfunction rank among the leading contributors to the global burden of disease. According to the Global Burden of Disease Study, alcohol use contributed to 2.8 million deaths in 2016 and is the leading risk factor for premature death and disability among individuals ages 15 to 49 years (1). Cardiovascular and metabolic conditions exert an even greater toll on global morbidity and mortality: In 2019, excess body weight was linked to 5 million deaths and 160.3 million disability-adjusted life years (2). A substantial proportion of individuals are affected by coexisting forms of these diseases, leading to additive burdens on overall health. Metabolic syndrome, defined as the presence of 3 or more metabolic risk factors, has been identified in 13% to 21% of individuals with alcohol use disorder (AUD) (3,4). Approximately 3% of the adult U.S. population (8 million people) is both obese and meets the criteria for heavy drinking established by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) (5,6). Furthermore, growing evidence describes the overlapping neuroendocrine mechanisms of these diseases, including dopaminergic deficiencies, gut-brain-liver signaling, and hypothalamic-pituitary-adrenal (HPA) axis dysregulation (6). This subgroup, heavy drinkers with metabolic syndrome, is particularly susceptible to hepatic complications because alcohol consumption and metabolic syndrome independently damage the liver and act synergistically to accelerate progression to fibrosis and cirrhosis (7). Even moderate alcohol intake promotes hepatocellular injury and substantially increases fibrosis risk in people with obesity or insulin resistance (8,9), while obesity independently contributes to steatosis, insulin resistance, and psychiatric vulnerability (10,11). Crucially, in patients with liver disease, alcohol consumption increases susceptibility to disease progression and mortality, but many individuals are unable to reduce or stop drinking, making long-term outcomes especially poor (9,12). Given that liver disease causes more than 2 million deaths annually worldwide, with alcohol misuse and metabolic dysfunction–associated steatotic liver disease (MASLD) as leading contributors (13), there is an urgent need for therapeutic strategies that address the converging pathophysiology of metabolic and alcohol-associated liver disease (metALD) (14,15). Current therapeutic treatment options for AUD and alcohol-associated liver disease (ALD) are limited. There are only 3 U.S. Food and Drug Administration (FDA)–approved therapeutics for AUD and no approved therapeutics for ALD, resulting in medication being prescribed to <9% of patients who are likely to benefit from them (16). Novel therapeutic options, including glucagon-like peptide-1 receptor (GLP1R) agonists, such as semaglutide, and more recently dual glucose-dependent insulinotropic polypeptide receptor (GIPR)/GLP1R agonists, including tirzepatide (see Table 1), have demonstrated substantial metabolic benefit and weight loss in individuals with type 2 diabetes, obesity, and metabolic dysfunction–associated steatohepatitis (MASH) (17, 18, 19, 20). Additionally, GLP1R agonists (GLP1RAs) have shown exciting promise for treating AUD in preclinical and clinical data and have been reviewed elsewhere (21, 22, 23). Looking forward, GIPR/GLP1R dual agonists may be well suited to simultaneously modulate metabolic and reward circuitry in high-risk drinking populations (see Figure 1), such as individuals with co-occurring AUD and obesity. In this narrative review, we highlight the promise of GLP1RA and GIPR/GLP1R dual agonists in metALD, as well as prospective research priorities surrounding incretin-based treatments in psychiatry. Table 1GIPR/GLP1R Dual Agonists in DevelopmentCompound NameStageResultsReferenceTirzepatideFDAAverage weight loss of 20% in participants with obesity at week 72Aronne et al. (154)Maridebart CafraglutidePhase 3Up to 20% average weight loss in participants with obesityJastreboff et al. (155)HRS9531Phase 3Up to 16% weight loss at week 24 in obese adultsZhao et al. (156)VK2735Phase 2Up to 15% weight loss in participants with obesity at week 13Viking TherapeuticsCT-868Phase 2Clinically meaningful decreases in HbA1c and modest weight loss in adults with T2D at week 26Chakravarthy et al. (157)CT-388Phase 2Over 8% weight loss in 4 weeks in overweight and obese adultsChakravarthy et al. (158)NNC0519-0130Phase 2UnpublishedNCT05363774HDM1005Phase 2Dose-dependent weight loss and glucose reductions at week 4Du et al. (159)SCO-094Phase 1OngoingScohiaDR10628Phase 1OngoingDoer BiologicsFDA, Food and Drug Administration; GIPR, glucose-dependent insulinotropic polypeptide receptor; GLP1R, glucagon-like peptide-1 receptor; HbA1c, glycated hemoglobin; T2D, type 2 diabetes. GIPR/GLP1R Dual Agonists in Development FDA, Food and Drug Administration; GIPR, glucose-dependent insulinotropic polypeptide receptor; GLP1R, glucagon-like peptide-1 receptor; HbA1c, glycated hemoglobin; T2D, type 2 diabetes. Biological actions of GIPR/GLP1R or GLP1R therapies. A visual overview of direct and indirect physiological effects of GIPR/GLP1R dual agonists. These effects are hypothesized to be relevant to the repurposing of dual agonists to overweight, heavy-drinking populations with metabolic dysfunction. GIPR, glucose-dependent insulinotropic polypeptide receptor; GLP1R, glucagon-like peptide-1 receptor. GLP-1 Physiology GLP-1 is a peptide hormone central to insulin signaling, metabolic homeostasis, and neurobehavioral regulation. It is secreted postprandially by enteroendocrine L cells, predominantly in the ileum, with additional secretion from colonic cells (24). Circulating GLP-1 enhances glucose-dependent insulin secretion, slows gastric emptying to regulate nutrient absorption, and promotes satiety, collectively contributing to weight loss and glycemic control (25, 26, 27). These actions are mediated through the GLP1R, a class B G protein–coupled receptor that activates diverse intracellular signaling cascades, including cAMP (cyclic adenosine monophosphate), protein kinase A, and PI3K (phosphoinositide 3-kinase) pathways (25,26). Rapid degradation of endogenous GLP-1 by dipeptidyl peptidase-4 (DPP-4) limits its half-life to minutes, motivating the development of long-acting GLP1R agonists with sustained appetite-suppressing and glucose-lowering effects (28). GLP-1 is also synthesized in the central nervous system (CNS), particularly in widely projecting neurons of the caudal nucleus of the solitary tract (29), and acts as a neuromodulator to regulate feeding behaviors (30). GLP1Rs are expressed in a variety of tissues (see Table 2), including in mesolimbic, hypothalamic, and brainstem circuits where they regulate appetite, stress reactivity (29), glucoregulation, and reward processing (24,26). GLP-1 therapies also influence gut bacterial load and regulate inflammation across the brain, liver, and gut (31,32)—both key pathological components of metALD. Evidence from preclinical and clinical studies indicates that GLP1R signaling modulates metabolic demand and brain reward processing, supporting exploration of GLP1R agonists as potential treatments for AUD (26,33). As endogenous GLP-1 and GLP-1 agonists can activate GLP1R-expressing neurons, peripheral and central GLP-1 pathways represent converging mechanisms of therapeutic interest. Peripheral GLP1R activation can engage vagal afferents, while central GLP1R signaling regulates hypothalamic satiety circuits; these pathways jointly influence feeding behavior (24,34). Table 2GLP1R Expression in Key TissuesTissue/Cell TypeExpression LevelNotesPancreatic IsletsConstantExpression in beta cells supports its canonical incretin role (35,166).Adipose TissueConstantExpression is detected in human epicardial adipose tissue (167), visceral fat depots, and subcutaneous fat depots (168). Expression is higher in visceral fat and correlated with metabolic biomarkers, such as weight and waist circumference (168).BoneTransientNot typically detected in mature bone but relevant to differentiation and resorption; for example, GLP1R activation in bone marrow stem cells facilitates osteogenic differentiation (169).BrainVariedDetected in the limbic system and other brain tissues, including neuronal and non-neuronal hypothalamic cells (163), the nucleus accumbens, the hippocampus (110), the brainstem (166), circumventricular organs (166), and the amygdala (170)Gastrointestinal TractConstantGLP1R mRNA has been detected in the stomach, small intestine, and large intestine, including within parietal cells, Brunner’s glands, chief cells, mucosal enterocytes, basolateral epithelial cells, and myenteric neurons (164).GLP1R, glucagon-like peptide-1 receptor; mRNA, messenger RNA. GLP1R Expression in Key Tissues GLP1R, glucagon-like peptide-1 receptor; mRNA, messenger RNA. GIP Physiology GIP is a gut-derived hormone secreted from enteroendocrine K cells in the proximal small intestine in response to nutrient digestion, particularly dietary fat (24). GIP potentiates insulin secretion via signaling pathways in the pancreatic islet (25,35) and enhances proliferation and survival of beta cells (24). The insulinotropic effect of GIP is attenuated in patients with type 2 diabetes mellitus (36). Endogenous GIP is rapidly degraded by DPP-4 and has an elimination half-life of just minutes (37), limiting its period of action. GIP exerts its effects through activation of the GIPR, a class B G protein–coupled receptor, across multiple organ systems. In addition to the pancreas, GIPRs are expressed in adipocytes, where they modulate nutrient partitioning, as well as in myeloid cells, bone, vascular endothelium, the adrenal cortex, and the CNS (20,24,38) (see Table 3). The pleiotropic effects of GIPR activation include impacts on lipid metabolism, bone resorption, and neuroprotection (39). GIPR signaling in the hypothalamus suppresses food intake in mice (40,41), but early evidence once framed GIP as obesogenic until dual agonist studies demonstrated greater decreases in body weight (42,43). GIP’s role in adipocyte signaling provides multifaceted metabolic benefit, enhancing lipid release in fasted cells and augmenting glucose clearance in the fed state (44) and driving thermogenesis and energy expenditure in white adipose tissue (45). Preclinical studies have also linked GIP signaling to beneficial effects on CNS functions, which have not been replicated in humans, including cognitive function, synaptic plasticity, and neurogenesis (39,46,47), as well as peripheral improvements in glycemic control, protection from obesity, and reduction in hepatic steatosis (39,46,48). Table 3GIPR Expression in Key TissuesTissue/Cell TypeExpression LevelNotesPancreatic IsletsConstantExpression in alpha and beta cells supports its canonical incretin role (35).Adipose TissueConstantGIPR activation in adipocytes impacts lipid storage, lipoprotein lipase activation, and fat metabolism (39). Expression is inversely related to cardiometabolic markers, such as waist circumference, triglyceride levels, and insulin resistance (160).BoneTransientBone remodeling is modulated by GIPR in osteoclasts and osteoblasts (39,161).BrainVariedExpression detected in the human neocortex, hippocampus (162), and hypothalamus (163). Expression is detected throughout the rodent brain (39). Mouse hypothalamic GIPR-expressing cells suppress food intake (40).Gastrointestinal TractConstantIn murine models, GIPR mRNA is detected in bulk processing of stomach and small intestine tissue (164), as well as mucosal and epithelial cells of the small intestine (165).GIPR, glucose-dependent insulinotropic polypeptide receptor; mRNA, messenger RNA. GIPR Expression in Key Tissues GIPR, glucose-dependent insulinotropic polypeptide receptor; mRNA, messenger RNA. Dual GIPR and GLP1R Signaling Independent activation of GIPRs and GLP1Rs engages overlapping signaling programs, and coactivation introduces additional integration across tissues. In pancreatic beta cells, both hormones potentiate glucose-stimulated insulin secretion through convergent pathways, supporting postprandial glycemic control (25,35). Together, GIP and GLP-1 account for much of the incretin effect—the greater insulin response to oral versus intravenous nutrient delivery (25). In addition to the pancreas, both GIPRs and GLP1Rs are expressed across peripheral organs and the CNS, where they modulate feeding behavior and metabolism through the gut-brain-liver behavioral axis (40,43,49). The GIPR/GLP1R dual agonist tirzepatide has an elimination half-life of approximately 5 days, enabling once-weekly dosing and sustained receptor engagement (20). In clinical trials, GIPR/GLP1R dual agonists have produced meaningful reductions in body weight, glycated hemoglobin (HbA1c), and other cardiometabolic risk markers compared with baseline and, in comparative studies, relative to GLP1RAs alone (18,20). The mechanisms underlying this synergy have not been fully elucidated, owing to the systemic receptor distribution, tissue-specific signaling, and interplay between the 2 receptor pathways (25,40,44,50). Notably, GIPR agonism and antagonism, when combined with GLP1R agonism, show similar metabolic effects and weight loss (51), raising ongoing questions about GIPR signaling and whether it primarily augments tolerability to GLP1R agonism when administered simultaneously (52). The mechanistic contribution of GIPR activation to tirzepatide’s effects is debated, such as the possibility that GIPR/GLP1R co-agonists are merely GLP1R superagonists (53). However, tirzepatide-induced GIPR agonism in GLP1R knockout mice has demonstrated improved insulin sensitivity and glucose disposal (54), indicating therapeutic effects unique to GIPR agonism and the unique contributions of GIP to adipose tissue function (45). Tirzepatide in human cell lines also shows more engagement with the GIPR than the GLP1R and mimics the ligand behaviors of native GIP, while showing GLP1R agonism that is biased toward cAMP signaling (55). Long-acting GIPR agonism induced by tirzepatide also enhances adipocyte function differentially in the fed and fasted states, shifting from nutrient storage to energy release (44). These observations provide a plausible, although still incompletely resolved, mechanistic framework for tirzepatide’s enhanced metabolic impact relative to GLP1R agonism alone. Clinically, tirzepatide has significantly improved glycemic control and reduced body weight in multiple clinical trials, including the SURPASS program in patients with type 2 diabetes and the SURMOUNT-1 trial in individuals with obesity (18). Moreover, tirzepatide has been shown to significantly decrease waist circumference, fasting serum glucose, blood pressure, low-density lipoprotein cholesterol, alanine transaminase, and aspartate transaminase in these trials (18). Furthermore, a 2024 randomized controlled trial (RCT) assessed once-weekly subcutaneous tirzepatide in participants with biopsy-confirmed MASH and stage F2 or F3 fibrosis. The intervention resulted in robust dose-dependent resolution of MASH without worsening of fibrosis (10% in the placebo group, 44% with 5 mg, 56% with 10 mg, 62% with 15 mg) (19). These data underscore a broad and favorable impact of GIPR/GLP1R activation on metabolic biomarkers and hepatic disease progression. Alcohol Use and Cardiometabolic Dysfunction Chronic alcohol use is robustly linked to systemic harm in the body, including cardiovascular and digestive diseases, cancers, and neuropsychiatric conditions (56). It is increasingly established as a disrupter of metabolic homeostasis, lipid and liver function enzyme levels, and cardiovascular health (57, 58, 59, 60, 61, 62). Gut microbiota and barrier permeability shifts are among the first detectable symptoms of AUD (63). These shifts can induce neurodegeneration, via the proliferation of inflammatory cytokines and bacterial endotoxins, and exhibit a progressive proinflammatory profile among individuals with alcohol-related liver disease (ARLD) (63). Alcohol consumption also drives the stress response, including HPA activation and noradrenaline, cortisol, and adrenocorticotropic hormone circulation, which can exacerbate gut dysbiosis and addictive behavior (63). Genetic predisposition to alcohol consumption has also been associated with cardiovascular risk factors in Mendelian randomization (MR) studies (64), and alcohol consumption can be a contributing factor to weight gain (65). In sum, chronic alcohol use drives systemic gut-brain-liver shifts, including inflammation, insulin resistance, and gut dysbiosis, which create a metabolic signature driving neuroinflammation and reward desensitization. Alcohol misuse and metabolic dysfunction drive overlapping and independent pathways that lead to hepatic fat accumulation and oxidative stress (66). Alcohol consumption results in free radical generation and toxin-mediated injury to hepatocytes and mitochondria, driving chronic inflammation, dysregulated lipid metabolism, and progressive steatosis [see Yan et al. (67) and Mackowiak et al. (68) for in-depth discussion]. Separately, metabolic dysfunction harms via an accumulation of harmful lipids around the liver and the activation of inflammatory and fibrotic pathways, possibly resulting in the scarring and loss of function of liver tissue (69). The synergistic impacts of metabolic dysfunction and alcohol consumption make these populations particularly vulnerable to liver disease progression and liver-related mortality (7,66). Alcohol abstinence is an established priority to attenuate the progression of liver disease through fibrosis and cirrhosis (9,70). Among heavy alcohol consumers, obesity, diabetes, and metabolic syndrome are independent causes of liver injury and risk factors for hepatocellular carcinogenesis (71). Furthermore, metabolic syndrome in heavy drinkers is independently associated with metabolic risk factors such as elevated serum GGT (gamma-glutamyl transferase), hyperuricemia, and reduced kidney function (3). In sum, alcohol consumption and metabolic dysfunction are independently and jointly associated with liver-related morbidity (7,71, 72, 73). GLP1R Agonists and Alcohol Use Robust evidence supports a connection between GLP1R agonists and reduced alcohol consumption (49). Extensive preclinical studies in mice, rats, and nonhuman primates have demonstrated that GLP1RAs can diminish the rewarding effects of alcohol, leading to reduced overall intake (74, 75, 76). GLP1R activation likely impacts addictive behaviors through reward processing, including reduced cue-induced reactivity, drug reinstatement, and dopaminergic signaling (77, 78, 79). Human genetic evidence further supports a role for the GLP1R in AUD: GLP1R variants are linked to functional consequences in alcohol self-administration paradigms or functional magnetic resonance imaging (fMRI) reward-response assays (80) and differences in resting-state functional connectivity in networks relevant to addiction (81). Notably, GLP1R genetic variants were not associated with AUD in the largest genome-wide association studies (GWASs) reported to date (82,83), which may reflect the complexity of the phenotype and a lack of common variants with functional impact on GLP1R signaling. Nonetheless, these findings support the hypothesis that GLP1R activity influences alcohol consumption behaviors by modulating neural reward processing and network connectivity. The first real-world human evidence supporting this relationship came from anecdotal reports, including a small survey study showing that 88.4% of semaglutide users reported a reduced desire to consume alcohol, and 88.7% of heavy drinkers no longer met heavy drinking criteria after starting semaglutide (84). More recently, clinical and observational studies have provided support for this connection. One cohort study found a decreased risk of hospitalization due to AUD among individuals with AUD who were using GLP1R agonists (hazard ratio [HR] for semaglutide users: 0.64) (85). In another study, patients with obesity taking semaglutide showed a 50% to 56% lower risk for the incidence and recurrence of AUD in a 12-month follow-up period (86). In 2025, a retrospective cohort study compared GLP1RAs and DPP-4 inhibitors (DPP-4i) in patients with type 2 diabetes mellitus. In this cohort, GLP1RA users with AUD showed lower risk of developing ALD (HR = 0.62), and GLP1RA users with ALD showed reduced risk of hepatic decompensation (HR = 0.66) compared with DPP-4i users (87). These robust reductions in liver disease progression are consistent with the beneficial effects of GLP1R agonists on SLD risk factors such as obesity and type 2 diabetes (88). However, few RCTs have directly assessed the effects of GLP1RAs on alcohol misuse or AUD. In a secondary analysis of a double-blind, placebo-controlled RCT, dulaglutide administration reduced alcohol consumption by 29% after 12 weeks compared with placebo (N = 255) (89). Another double-blind, placebo-controlled RCT assessed 2 mg of exenatide versus placebo alongside cognitive behavioral therapy in treatment-seeking patients with AUD (N = 127) (78). This treatment significantly reduced the fMRI cue reactivity in reward brain areas but demonstrated no significant effect on the primary outcome—number of heavy drinking days. The null findings may reflect the participants’ relatively mild drinking habits and the limited efficacy of low-dose exenatide compared with more potent GLP1R agonists. Interestingly, in the body mass index (BMI) >30 subgroup, exenatide reduced heavy drinking days by 23.6% and total alcohol intake by 1205 g (78), indicating effectiveness in individuals with co-occurring obesity and AUD. An RCT of weekly low-dose semaglutide for 8 weeks resulted in reductions in laboratory self-administration of alcohol and measures of alcohol craving but failed to significantly reduce drinks per calendar day (90). Finally, a May 2026 RCT found that semaglutide reduced heavy drinking days, drinking risk level, and other alcohol-related and somatic outcomes more than placebo in patients with AUD and comorbid obesity, providing the strongest evidence for beneficial effects of GLP1RAs in treatment-seeking patients with AUD and obesity (91). This demonstrated potential of GLP1RAs motivates the ongoing RCTs investigating their protective impacts in the AUD population (21) (Table 4). Table 4Trials of GLP1R Agonists in Alcohol-Consuming PopulationsCompoundTrial IdentifierPopulationDesignResultsExenatideNCT03232112Treatment-seeking patients with AUD (Copenhagen, Denmark)2 mg treatment or placebo weekly for 26 weeks (N = 127, 58 completers)Significantly reduced heavy drinking days in the BMI >30 subgroup and attenuated fMRI cue reactivity (78)DulaglutideNCT03204396Cigarette smokers who also drank alcohol (Basel, Switzerland)Secondary analysis of 12-week dulaglutide treatment (0.75 mg first week, 1.5 mg onward) with smoking cessation therapy (N = 151)Participants receiving dulaglutide drank 29% less than participants receiving placebo (89).SemaglutideNCT05520775Non–treatment-seeking adults with AUD (North Carolina, US)After 8 weeks of treatment, measure alcohol consumption during laboratory self-administration and via calendar-based methods (N = 48)Treatment reduced laboratory consumption and some calendar measures of alcohol consumption and craving (90).SemaglutideNCT05895643Patients with AUD and comorbid obesity (Copenhagen, Denmark)Escalating dose or placebo weekly for 26 weeks (N = 108)Semaglutide and CBT reduced heavy drinking days by 13.7 more percentage points than CBT alone (91).SemaglutideNCT05520775Adults with AUD (North Carolina, US)Escalating dose or placebo weekly for 9 to 10 weeks (N = 48)Unpublished (171)SemaglutideNCT06015893Adults with AUD; 50 > BMI > 23 (Maryland, US)Maximum tolerated dose or placebo weekly for 20 weeks (estimated N = 52)Recruiting (172)SemaglutideNCT05892432Adults with AUD; BMI > 25 (Colorado, US)Titrated dose or placebo weekly for 8 weeks (estimated N = 50)Active, not recruiting (173)SemaglutideNCT05891587Adults with AUD; 50 > BMI > 25 (Oklahoma, US)Titrated dose or placebo weekly for 12 weeks (estimated N = 80)Recruiting (174)SemaglutideNCT06409130Adults with a history of alcohol overuse and liver fibrosis (multinational)Semaglutide, NNC0194-0499, cagrilintide, placebo, or a combination weekly for 39 weeks (estimated N = 270)Active, not recruiting (175)SemaglutideNCT06546384Adults with fatty liver disease, obesity, and at-risk drinking (Bern, Switzerland)Titrated dose or placebo weekly for 16 weeks alongside standard of care for weight reduction (N = 64)Not yet recruiting (176)AUD, alcohol use disorder; BMI, body mass index; CBT, cognitive behavioral therapy; fMRI, functional magnetic resonance imaging; GLP1R, glucagon-like peptide-1 receptor. Trials of GLP1R Agonists in Alcohol-Consuming Populations AUD, alcohol use disorder; BMI, body mass index; CBT, cognitive behavioral therapy; fMRI, functional magnetic resonance imaging; GLP1R, glucagon-like peptide-1 receptor. GIPR Agonists, GIPR/GLP1R Dual Agonists, and Alcohol Use There remains a significant gap in the literature regarding the independent effects of GIPR activity on alcohol consumption. GIPR-mediated modulation of CNS reward circuits regulates food intake in preclinical models (40,41), and GIPR/GLP1R dual agonists may impact alcohol consumption similarly. Additionally, established GIPR effects on synaptic plasticity (46,47) could impact neuroadaptation in addiction. However, to our knowledge, the independent impact of GIPR signaling on alcohol consumption has not been evaluated in preclinical models, and these hypotheses remain an open question. As GIP monoagonists have not advanced sufficiently in clinical development, existing data on GIP often derive from studies involving GIPR/GLP1R dual agonists, such as reduced alcohol discrimination in rats given tirzepatide (92). Alternatively, human genetic studies provide a preliminary assessment of the relationship between GIPR and alcohol use. A pilot study of 280 Slovenian male participants found that a GIPR polymorphism was associated with alcohol dependence (93). However, neither GLP1R nor GIPR mutations have been identified in the largest alcohol-related GWAS and exome sequencing analyses reported to date (83,94), likely due to the polygenicity and heterogeneity of AUD and a lack of functional variants with large effect sizes. Clinical or longitudinal data testing this relationship is lacking; thus, other modern genetic modeling techniques, such as multivariate GWAS (95) of AUD or multiomic analysis, are needed to test this therapeutic hypothesis. Other genetic studies have used MR, which leverages genetic variation in summary statistics to examine exposure-outcome relationships (see Figure 2). To assess the repurposing potential of GIPR/GLP1R dual agonists, our NIAAA team conducted a 2025 drug-target MR study of GIPR/GLP1R dual agonism (96). Single nucleotide polymorphism (SNP)–based instruments were developed as genetic proxies for GLP1R agonism, GIPR agonism, or dual GIPR/GLP1R agonism using HbA1c and BMI GWASs, consistent with the established therapeutic effects of this drug class. Following drug-target MR methodology (97), variants were restricted to the GIPR/GLP1R loci to preserve receptor relevance, minimize off-target effects, and satisfy core MR assumptions (98). Instrument validity was supported by functional/expression-linked SNPs, sensitivity and colocalization analyses, and expected protective associations with type 2 diabetes and obesity. Across alcohol-related behavioral, psychiatric, physical, and food-liking outcomes, these proxies were associated with reduced binge and high-risk drinking, healthier food-liking patterns, and lower alcohol-related liver injury enzymes, supporting the use of GLP1RAs for AUD treatment and implicating GIP signaling as potentially relevant. Comparison of drug-target Mendelian randomization with RCTs. The design for (A) a hypothetical RCT that investigates the impact of GIPR/GLP1R agonists on alcohol consumption behaviors and liver health is compared with (B) a drug-target MR analysis assessing the impact of genetically proxied associations of GIPR/GLP1R activity (153). In (B), single nucleotide polymorphisms located within or near the genomic loci and associated with the downstream physiological impact or gene expression emulate GIPR/GLP1R therapeutic effects (reduced HbA1c or lowered BMI). BMI, body mass index; GIPR, glucose-dependent insulinotropic polypeptide receptor; GLP1R, glucagon-like peptide-1 receptor; GWAS, genome-wide association study; HbA1c, glycated hemoglobin; MASH, metabolic dysfunction–associated steatohepatitis; MR, Mendelian randomization; RCT, randomized controlled trial. The Potential Role of GIPR/GLP1R Dual Agonists in Populations With Comorbid AUD and Metabolic Dysfunction To date, no clinical trials have assessed whether GIPR/GLP1R dual agonists can reduce alcohol consumption or improve hepatic outcomes in heavy drinking, metabolically unhealthy populations, but efforts are ongoing (see Table 5 for active trials). Thus, the highest-quality evidence to answer this question is lacking. Nonetheless, one remote study of 153 individuals with obesity found markedly lower self-reported alcohol consumption, binge drinking, Alcohol Use Disorders Identification Test scores, and effects of alcohol among individuals taking tirzepatide or semaglutide compared with control individuals (99). The vast behavioral changes identified, such as the reduced odds of binge drinking (tirzepatide vs. control [odds ratio = 0.02; 95% CI, 0.006–0.085; p < .001]), provide converging evidence of reduced alcohol use in individuals taking semaglutide or tirzepatide, but they should be interpreted in the context of the selection bias, self-report bias, and lack of a dose-response relationship present in the small observational study (99). In addition, a 2024 cohort study of more than 800,000 patients with a history of AUD found an association between prescriptions for GLP1R or GIPR/GLP1R agonists and lower rates of alcohol intoxication (adjusted incidence rate ratio: 0.50; 95% CI, 0.40–0.63) (100), further connecting this therapeutic class to reduced AUD pathology. Table 5Trials of GIPR/GLP1R Dual Agonists in Alcohol-Consuming PopulationsCompoundTrial IdentifierPopulationDesignResultsTirzepatideNCT06939088Adults with schizophrenia and AUD (Denmark)Titrated dose, or placebo, weekly for 26 weeks (estimated N = 108)Recruiting (177)TirzepatideNCT06727331Adults with AUD and admitted to the inpatient program for alcohol withdrawal (Massachusetts, US)2.5 mg treatment, or placebo, weekly for 4 weeks (estimated N = 20)Recruiting (178)TirzepatideNCT07046819Adults with AUD, liver steatosis, and a metabolic risk factor (Maryland, US)Titrated dose, or placebo, weekly for 12 weeks (estimated N = 120)Recruiting (179)AUD, alcohol use disorder; GIPR, glucose-dependent insulinotropic polypeptide receptor; GLP1R, glucagon-like peptide-1 receptor. Trials of GIPR/GLP1R Dual Agonists in Alcohol-Consuming Populations AUD, alcohol use disorder; GIPR, glucose-dependent insulinotropic polypeptide receptor; GLP1R, glucagon-like peptide-1 receptor. Several other factors indicate the potential of dual agonists for secondary disease prevention in high-risk AUD populations. First, promising preclinical and clinical studies have shown that GLP1RAs reduce alcohol intake, liver disease progression, and cortical reactivity. The dual agonist tirzepatide shows greater potency in weight reduction and glycemic control compared with several GLP1RAs, although the relative contribution of GIPR activation versus enhanced or more tolerable GLP1R signaling remains unresolved. Larger impacts on satiety, gastric emptying, and lipid metabolism could further attenuate alcohol consumption due to the neurobiological overlap between AUD and obesity. Second, anti-inflammatory effects and favorable alterations to intestinal microbiota can provide gut-brain-liver stabilization along key pathological axes of metALD (31,32). Third, tirzepatide has been shown to decrease liver and abdominal fat (101), providing clinically meaningful attenuation of liver disease progression. Lastly, the GWAS-derived estimates of drug-target MR studies show reductions in binge drinking and broad alcohol misuse classification causally linked to the GIPR and GLP1R loci. Thus, GIPR/GLP1R dual agonists may be well suited to treating those at highest risk of liver disease progression: comorbidly obese, metabolically dysfunctional, and heavy-drinking individuals. Reward Circuit Modulation in AUD Versus Metabolic Correction in Other Psychiatric Disorders AUD and obesity share reward circuit and metabolic features that support a biological convergence model rather than a simple food-as-drug analogy. Both involve cue-driven consumption, HPA axis engagement, altered dopaminergic signaling, and structural or functional changes in reward and prefrontal circuits (6,102, 103, 104). In AUD, incentive salience and stress-like responses contribute to compulsive drug seeking, desensitization, and reduced executive control, while analogously in obesity or food addiction, blunted dopamine responses and reduced dopamine D2 receptor availability have been linked to overeating (6,102,103,105). AUD and obesity are also influenced by overlapping pharmacotherapies and interventions, including naltrexone, topiramate, and metabolic surgery, further supporting shared biological vulnerability (106,107). These overlapping mechanisms support the idea that pharmacotherapies targeting metabolic and reward signaling may have relevance across both conditions. GLP1R-based therapeutics are being explored across psychiatric indications, but the most coherent mechanistic signal is in alcohol and substance use disorders (SUDs) (108). In preclinical models, GLP1R agonists reduce alcohol and drug self-administration, cue reactivity, reinstatement, and withdrawal-linked anxiety, with effects localized to GLP1R-expressing mesolimbic nodes (109, 110, 111, 112). Early human studies have shown parallel reductions in craving, cue reactivity, and heavy drinking (78,86,113). In contrast, studies in schizophrenia, depression, and anxiety show clearer metabolic benefits than improvements in core psychiatric symptoms (114, 115, 116, 117, 118, 119). This distinction supports AUD and metALD as particularly promising targets because reward-circuit dysregulation and impaired metabolic-hepatic homeostasis converge in the same population. Clinical Considerations Several clinical questions must be resolved before GIPR/GLP1R dual agonists can be considered for heavy-drinking populations. Tirzepatide is FDA approved for glycemic control in adults with type 2 diabetes and for chronic weight management in adults with obesity (17,18), but which heavy-drinking populations may benefit clinically is understudied. Adults with co-occurring obesity and AUD or type 2 diabetes and AUD represent high-priority groups because they are at elevated risk for cardiometabolic disease and liver injury, and prior exenatide data suggest that individuals with obesity may be especially responsive to GLP1R-based approaches (78). Patients with ALD or advanced fibrosis may also derive hepatic benefit if dual agonists prove effective, but this group requires careful safety evaluation because of gastrointestinal vulnerability, malnutrition, sarcopenia, physiological fragility, and potential sex-specific differences in efficacy and adverse events (120, 121, 122). A second question is whether any reduction in alcohol intake is alcohol specific or reflects broader reductions in appetite, fluid intake, satiety, nausea, or gastric emptying. The slowed gastric emptying, nausea, and increased satiety resulting from GIPR/GLP1R dual agonism (123) may preferentially impact the highest-risk drinking behaviors, such as binge drinking and heavy drinking days. Small RCTs have shown that GLP1RAs decrease fluid intake (124,125), and high-volume alcohol consumption would likely be affected in a similar manner. Even nonspecific reductions may be clinically useful, particularly if binge drinking or heavy drinking days are reduced, but this must be directly tested using alcohol-specific end points. Given the significant role of alcohol consumption in severe liver disease outcomes (72), reduction in alcohol use should remain an essential therapeutic goal in heavy-drinking individuals treated with GIPR/GLP1R dual agonists. Safety and tolerability are especially important in heavy-drinking populations. Tirzepatide and GLP1RAs commonly cause gastrointestinal adverse effects, including nausea, vomiting, and diarrhea (122,123), which may be problematic in patients with alcohol-related gastritis, gut dysbiosis, poor oral intake, or cirrhosis-related vulnerability (56,126,127). Appetite suppression and weight loss may be undesirable in underweight, sarcopenic, or nutritionally compromised patients with AUD. Additional concerns include dehydration, electrolyte disturbances, hypoglycemia in patients using glucose-lowering therapies, pancreatitis risk, altered absorption of oral medications due to delayed gastric emptying, and reduced adherence to concurrent AUD or psychiatric medications (56,128). Sex-disaggregated safety data will also be needed because female users may experience both enhanced efficacy and more frequent adverse events (121,122). Finally, real-world implementation will depend on access. Dual agonists are costly and often subject to coverage restrictions and prior authorization, which may disproportionately limit use among individuals with AUD who already experience barriers to sustained medical care. Equity-focused trial design and implementation studies should evaluate strategies to minimize disparities in access, including integration with addiction medicine clinics, insurance navigation, and patient-assistance pathways. Future Directions Many questions regarding GIPR/GLP1R dual agonists remain unanswered. Because alcohol-metabolism interactions are poorly characterized, and heavy-drinking populations have been largely excluded from metabolic trials, future work should prioritize 4 areas: dedicated RCTs, mechanistic studies, broader population sampling, and integration with existing AUD treatments. Rigorous RCTs in High-Risk Populations RCTs should directly test GIPR/GLP1R dual agonists in individuals with harmful alcohol use and metabolic dysfunction. Most GLP1RA and dual agonist trials have been conducted in diabetes or obesity cohorts and have often excluded individuals with heavy alcohol use (129, 130, 131), leaving the highest-risk populations understudied. Phase II proof-of-concept trials with adults with AUD and metabolic syndrome or MASLD/MASH risk should assess heavy drinking days, binge frequency, craving, cue reactivity, and alcohol self-administration and use objective alcohol measures such as phosphatidylethanol, transdermal alcohol monitoring, or ecological momentary assessment (132, 133, 134). Hepatic outcomes, including MRI–proton density fat fraction, elastography, fibrosis panels, and ALT/AST (alanine aminotransferase/aspartate aminotransferase) trajectories, should be incorporated early (135). Mechanistic readouts such as fMRI cue reactivity, neuroendocrine profiling, continuous glucose monitoring, and digital phenotyping could help distinguish direct CNS effects from peripheral effects on satiety, gastric emptying, or metabolism (34). Longitudinal safety monitoring is essential because heavy drinkers often have gastrointestinal instability, nutritional deficiencies, and psychiatric comorbidities (56,127,136). Disentangling Dual GIPR/GLP1R Signaling in the Context of Alcohol Use Further translational research is needed to determine how alcohol consumption and other substance use comorbidities modify the effects of long-acting GIPR agonism alongside GLP1R agonism across pancreatic islets, adipocytes, bone, liver, and brain. This is especially important as distinct dual agonists, and even GIP/GLP1/glucagon receptor triple agonists, with varying receptor activation profiles enter clinical use (122). Dual agonists engage coordinated responses across hepatocytes, adipose tissue, pancreatic islets, skeletal muscle, and multiple brain regions involved in energy balance and reward (25,43). GLP1R agonism consistently reduces appetite, improves glycemic control, and dampens mesolimbic dopamine signaling (28), while GIPR agonism enhances insulinotropic effects, modulates adipocyte lipid handling, and may influence reward via GIPR-expressing midbrain neurons (137,138). However, integrated downstream pathways, particularly during chronic dosing, remain unclear and may not be predictable from single-receptor biology alone (50,51,53,55). Alcohol introduces additional metabolic complexity by altering incretin secretion, hepatic redox state, adipose lipolysis, vagal signaling, and dopamine-driven reinforcement (139, 140, 141, 142, 143). Acute and chronic alcohol exposure interfere with insulin sensitivity, disrupt gut-brain endocrine loops, and modulate GIPR/GLP1R expression patterns across metabolic organs. Thus, alcohol is likely to reshape the metabolic, neural, and behavioral consequences of dual agonism in ways that remain poorly characterized. Key mechanistic questions include how alcohol modifies tissue-specific receptor engagement; whether dual agonists blunt alcohol-induced dysregulation of hepatic lipid flux and reward signaling; and how fed-fasted state, drinking pattern, or hepatic inflammation interact with incretin biology. Integrative metabolic phenotyping, neuroimaging, and multiomic studies will be essential for predicting response and optimizing therapeutic use in individuals with co-occurring harmful drinking and metabolic dysfunction. Expanding Study Populations Future studies should include non-European populations and individuals across the lifespan, given global variation in obesity, drinking patterns, ALD risk, diet, socioeconomic context, and health care access. Obesity risk is not uniform: Its prevalence follows inverted U–shaped age patterns in many populations, peaks earlier in some regions than others, and increasingly affects younger cohorts exposed to highly obesogenic environments (144,145). Younger adults and women are particularly important because early-onset harmful alcohol use and rising ALD rates disproportionately affect these groups (146,147). Broader sampling will be necessary to determine whether baseline obesity patterns, cultural drinking norms, drinking history, and access to care modify safety or efficacy. Integrating Behavioral and Pharmacological AUD Treatments Because AUD treatment is typically multimodal, future studies should evaluate whether dual agonists can be safely combined with existing behavioral interventions and AUD medications, including naltrexone, acamprosate, topiramate, and disulfiram. These approaches may target complementary domains, including reinforcement, craving, impulsivity, reward-cue reactivity, stress-related drinking, and metabolic instability. Psychiatric comorbidity also requires direct study, as many individuals with AUD receive antidepressants, antipsychotics, benzodiazepines, mood stabilizers, stimulants, or other medications that affect weight, metabolism, dopamine signaling, adherence, and relapse vulnerability (136,148, 149, 150, 151, 152). Therefore, pharmacokinetic and pharmacodynamic interactions should be evaluated in real-world AUD populations. Conclusions GLP1R and GIPR/GLP1R agonists represent an exciting therapeutic opportunity to leverage incretin biology to reframe the treatment of addiction and comorbid disorders, not only to treat obesity and metabolic dysfunction but also to directly target the neurobiological drivers of harmful alcohol use and the downstream progression of liver disease. High-risk individuals with co-occurring obesity, metabolic syndrome, and AUD, facing dysregulated feeding circuits, systemic inflammation and impaired metabolic homeostasis, and alcohol-driven hepatic injury, converge along a shared gut-brain-liver axis. GLP1R agonists have already demonstrated meaningful reductions in alcohol intake, improved metabolic flexibility, and attenuation of hepatic steatosis and inflammation. Early mechanistic studies suggest that dual agonists could potentially extend these effects: By simultaneously modulating pancreatic hormone signaling, adipose lipid flux, vagal afferent pathways, and possibly mesolimbic reward circuits, they may engage a broader biological network than single-receptor agonists alone. Genetic evidence, receptor pharmacology, and preclinical behavioral work collectively point to GIPR/GLP1R dual agonists as candidates to engage homeostatic and hedonic pathways in individuals with overlapping metabolic and alcohol-related disease. However, their true clinical impact remains unknown. High-quality, rigorously designed trials in real-world comorbid populations are urgently needed to determine psychiatric efficacy, hepatic outcomes, durability, safety, and potential interactions with existing AUD treatments. Together, these developments underscore a shift in psychiatry and SUD treatment to target metabolic circuits underlying psychological disease. The coming years offer a unique chance to define whether and how dual agonists can reshape the clinical management of these interconnected conditions. Acknowledgments and Disclosures This research was supported by the Intramural Research Program of the National Institutes of Health (NIH) as part of the Division of Intramural Clinical and Biological Research of the NIAAA (Grant No. ZIA-AA000242 [to FWL]). The contributions of the NIH author(s) are considered works of the U.S. government. The findings and conclusions presented in this article are those of the author(s) and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services. The funders had no role in study design, data collection or analysis, the decision to publish, or preparation of the article. The authors report no biomedical financial interests or potential conflicts of interest. Generative artificial intelligence tools were used for language editing. All content was reviewed and approved by the authors, who take full responsibility for the final article. References